RFL: Rafael Holdings, Inc. Stock

by  •  • Comments Off on RFL: Rafael Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 45.15
Enterprise Value ($M) 43.24
Book Value ($M) 77.38
Book Value / Share 3.24
Price / Book 0.58
NCAV ($M) 13.89
NCAV / Share 0.58
Price / NCAV 3.25

Profitability (mra)
Return on Invested Capital (ROIC) -0.50
Return on Assets (ROA) -0.40
Return on Equity (ROE) -0.41

Liquidity (mrq)
Quick Ratio 3.36
Current Ratio 3.36

Balance Sheet (mrq) ($M)
Current Assets 24.34
Assets 87.83
Liabilities 10.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.64
Operating Income -102.63
Net Income -34.41
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -7.80
Cash from Investing -10.82
Cash from Financing -0.18

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
09-30 13D/A Jonas Howard S

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-01-08 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the year ended July 31, 2024. ☐ Transition report pursuant
2024-12-20 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the year ended July 31, 2024. ☐ Transition report pursuant
2024-12-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended October 31, 2024. ☐ Transition report pursuant
2024-11-07 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the year ended July 31, 2024. ☐ Transition report pursuant to section 13 or 1
2024-06-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended April 30, 2024. ☐ Transition report pursuant to
2024-03-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended January 31, 2024. ☐ Transition report pursuant

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 9,684 19,724 49.10
2025-01-13 1,897 9,899 19.16
2025-01-10 6,868 31,071 22.10

(click for more detail)

Similar Companies
PRGO – Perrigo Company plc QGEN – Qiagen N.V.
RCUS – Arcus Biosciences, Inc. USNA – USANA Health Sciences, Inc.


Financial data and stock pages provided by
Fintel.io